Zydus Life shares rise after drug maker gets US regulator's nod for bronchospasm treatment injection
Isoproterenol Hydrochloride injection will be manufactured at the company's injectable manufacturing facility at Jarod, near Vadodara in India. With this, Zydus has received a total of 362 approvals and has so far filed more than 440 ANDAs since starting the filing process in FY 2003-04.
Isoproterenol hydrochloride injection is recommended to treat bronchospasm that occurs during anaesthesia. Source: Pixabay